Atavistik Bio

Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics.

Health and bio

Latest funding

$40M Series B+ · March 5, 2026

Led by RA Capital Management · Source: GlobeNewswire

Total raised: $220M across 3 sourced rounds

All 3 rounds ↓

Website: atavistikbio.com.

X: @AtavistikBio · 54 followers.

LinkedIn: atavistik-bio.

Category: Health and bio.

Sectors: Biotechnology, Health Care, Life Science, Therapeutics.

Stage: Series B+.

Based in: Cambridge, United States.

Total raised: $220M in 3 sourced rounds.

Last round: Mar 5, 2026 · 255 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Sep 29, 2026.

Signals

X account@AtavistikBio · created Aug 26, 2021 (5 years old) · 54 followers

Website registeredMar 19, 2021 (5 years old)

About Atavistik Bio

Our approach enables selective modulation of disease-causing proteins, with the potential to offer transformative treatment for patients with serious diseases.

TIMELINE · MONEY RAISED

Atavistik Bio | 158 days from website to first raise on record

@AtavistikBio·Raised $220M in 3 sourced rounds·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

Date	Round	Amount	Lead	Source
Mar 5, 2026	Series B+	$40M	RRA Capital Management	GlobeNewswire
Dec 18, 2025	Series B+	$120M	NNextech Invest	fundraisingfox.com
Aug 24, 2021	Series A	$60M	TThe Column Group	finsmes.com

Timeline

August 26, 2021
X account created
March 19, 2021
Website created

Founders and team

JR
Jared Rutter Founder
RJ
Ralph J DeBerardinis Founder
AK
Aninda Katragadda Chief Financial Officer
BS
Bryan Stuart Chief Executive Officer
JJ
John Josey Acting Chief Executive Officer
MD
Marion Dorsch President and Chief Scientific Officer

Investors

Companies like Atavistik Bio

GGlycoEra$130M Series B+ · May 2025
HHotSpot Therapeutics$100M Series B+ · Nov 2021
AAugustine Therapeutics$85M Series A · Mar 2025
OOutrun TherapeuticsSeed · Apr 2024
SSynthekine$100M Series B+ · Jan 2023
MMatchpoint Therapeutics$150M Series B+ · Oct 2026

Other companies backed by RA Capital Management

AAlethio Therapeutics$90M Series A · Nov 2026
SStar Therapeutics$200M Series B+ · Oct 2026
OOptivolt$32M Series A · Oct 2026
EEstuary Biotherapeutics$103M Series A · Oct 2026
MMMI$125M Series B+ · Oct 2026
AAbcuro$66M Series B+ · Aug 2026

RA Capital Management portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/atavistik-bio (get a free API key).